https://sanbio.evoworx.net/en/news/a-message-to-patients-from-ceo-keita-mori-regarding-topline-analytical-results-of-clinical-trial-announced-on-january-29-2019%ef%bc%8894kb%ef%bc%89/2020-04-01T21:01:01+09:00https://sanbio.evoworx.net/en/news/qa-concerning-the-january-29-2019-press-release-sanbio-announces-topline-results-from-a-phase-2b-study-in-the-u-s-evaluating-sb623-a-regenerative-cell-medicine-for-the-treatment-of-patien/2020-04-01T21:04:11+09:00https://sanbio.evoworx.net/en/news/%e3%80%90announcement%e3%80%91sanbio-will-present-at-the-37th-annual-j-p-morgan-healthcare-conference/2020-04-01T21:00:36+09:00https://sanbio.evoworx.net/en/news/%e3%80%90announcement%e3%80%91sanbio-will-be-featured-on-nhk-world-japan-medical-frontiers-the-brain-can-be-regenerated-on-september-4-tue-4-times-a-day-japan-time/2020-04-01T21:00:23+09:00https://sanbio.evoworx.net/en/news/dr-damien-bates-chief-medical-officer-and-head-of-research-at-sanbio-publishes-report-in-the-leading-medical-journal-stroke/2020-04-01T21:02:25+09:00https://sanbio.evoworx.net/en/news/sanbio-presented-at-the-36th-annual-j-p-morgan-healthcare-conference/2020-04-02T12:54:46+09:00https://sanbio.evoworx.net/en/news/sanbio-will-present-at-2nd-dia-cell-therapy-products-symposium-in-japan-on-december-15/2020-04-02T12:58:04+09:00https://sanbio.evoworx.net/en/news/keita-mori-ceo-of-sanbio-will-speak-at-2017-world-alliance-forum-in-san-francisco-on-november30/2020-04-01T21:03:05+09:00https://sanbio.evoworx.net/en/news/sanbio-receives-20-million-grant-from-cirm-for-stroke-clinical-trial%ef%bc%88264kb%ef%bc%89/2020-04-02T12:56:49+09:00https://sanbio.evoworx.net/en/news/dr-damien-bates-chief-medical-officer-and-head-of-research-at-sanbio-will-speak-at-the-7th-annual-traumatic-brain-injury-conference-on-may-2425-2017-washington-dc/2020-04-01T21:01:58+09:00https://sanbio.evoworx.net/en/news/sanbios-assoc-director-of-research-yaisa-andrews-zwilling-phd-will-present-at-keystone-symposia-on-aging-and-mechanisms-of-aging-related-disease-on-may-17th-2017/2020-04-02T12:58:12+09:00https://sanbio.evoworx.net/en/news/new-study-reveals-economic-impact-of-patients-with-traumatic-brain-injury%ef%bc%88140kb%ef%bc%89/2020-04-01T21:03:39+09:00https://sanbio.evoworx.net/en/news/sanbios-assoc-director-of-research-yaisa-andrews-zwilling-phd-will-present-at-the-morgan-stanley-womens-intelligence-trust-and-talk-about-the-data-from-our-clinical-trial-on-apri/2020-04-02T12:58:20+09:00https://sanbio.evoworx.net/en/news/study-of-sanbios-stem-cell-treatment-for-stroke-receives-innovation-award-from-american-heart-association%ef%bc%88168kb%ef%bc%89/2020-04-02T12:59:33+09:00https://sanbio.evoworx.net/en/news/sanbio-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-on-wednesday-january-11-2017-at-1100am-pt/2020-04-02T12:57:46+09:00https://sanbio.evoworx.net/en/news/dr-damien-bates-chief-medical-officer-and-head-of-research-at-sanbio-will-speak-on-a-panel-at-2016-world-alliance-forum-in-san-francisco-on-november-21/2020-04-01T21:02:06+09:00https://sanbio.evoworx.net/en/news/sanbio-presents-interim-results-of-the-first-intracerebral-stem-cell-transplant-study-for-stroke-in-the-united-states/2020-04-02T12:55:29+09:00https://sanbio.evoworx.net/en/news/first-patient-is-enrolled-in-global-stemtra-trial-for-traumatic-brain-injury-in-japan%ef%bc%88187kb%ef%bc%89/2020-04-01T21:02:43+09:00https://sanbio.evoworx.net/en/news/dr-damien-bates-chief-medical-officer-and-head-of-research-at-sanbio-will-speak-on-a-panel-at-ausbiotech-2016-on-october-25-in-melbourne-australia/2020-04-01T21:02:19+09:00https://sanbio.evoworx.net/en/news/dr-damien-bates-chief-medical-officer-and-head-of-research-at-sanbio-will-speak-at-th-75th-annual-meeting-of-the-japan-neurosurgical-society-on-september-29-in-fukuoka-japan/2020-04-01T21:01:52+09:00https://sanbio.evoworx.net/en/news/first-patient-is-randomized-in-stemtra-trial-for-traumatic-brain-injury%ef%bc%8892kb%ef%bc%89/2020-04-01T21:02:58+09:00https://sanbio.evoworx.net/en/news/sanbio-presents-interim-results-of-chronic-stroke-phase-1-2a-clinical-trial-at-international-society-of-stem-cell-research-annual-meeting%ef%bc%8892kb%ef%bc%89/2020-04-02T12:55:19+09:00https://sanbio.evoworx.net/en/news/publication-clinical-outcomes-of-transplanted-modified-bone-marrow-derived-mesenchymal-stem-cells-in-stroke-a-phase-1-2a-study/2020-04-01T21:03:57+09:00https://sanbio.evoworx.net/en/news/sanbio-publishes-interim-12-month-phase-1-2a-clinical-trial-results-in-the-leading-medical-journal-stroke%ef%bc%88112kb%ef%bc%89/2020-04-02T12:55:43+09:00https://sanbio.evoworx.net/en/news/sanbio-granted-key-patent-in-treatment-for-macular-degeneration%ef%bc%8890kb%ef%bc%89/2020-04-02T12:54:22+09:00https://sanbio.evoworx.net/en/news/keita-mori-ceo-of-sanbio-will-speak-at-new-economy-summit-2016-session-1-medical-innovation-in-tokyo-on-april-7/2020-04-01T21:03:26+09:00https://sanbio.evoworx.net/en/news/university-hospitals-case-medical-center-randomizes-the-first-patient-in-actissima-trial-for-chronic-stroke%ef%bc%88199kb%ef%bc%89/2020-04-02T13:00:00+09:00https://sanbio.evoworx.net/en/news/speech-delivered-by-keita-mori-president-of-sanbio-at-the-2015-world-alliance-forum-in-san-francisco-regenerative-medicine-lets-talk-business%ef%bc%8887kb%ef%bc%89/2020-04-02T12:58:42+09:00https://sanbio.evoworx.net/en/news/keita-mori-ceo-of-sanbio-will-talk-at-2015-world-alliance-forum-in-san-francisco-regenerative-medicine-lets-talk-business-nov-12-13/2020-04-01T21:03:18+09:00https://sanbio.evoworx.net/en/news/sanbio-announces-publication-in-stem-cells-and-development-%ef%bc%88137kb%ef%bc%89/2020-04-02T12:52:33+09:00https://sanbio.evoworx.net/en/news/sanbio-granted-key-patent-in-new-treatment-for-chronic-stroke-%ef%bc%88202kb%ef%bc%89/2020-04-02T12:54:07+09:00https://sanbio.evoworx.net/en/news/sanbio-scientist-to-present-on-stroke-and-stroke-therapies-at-the-womens-intelligence-trust-2015-forum-%ef%bc%88206kb%ef%bc%89/2020-04-02T12:57:26+09:00https://sanbio.evoworx.net/en/news/sanbio-ipo-raises-67m-to-carry-stroke-therapy-forward-%ef%bc%88464kb%ef%bc%89/2020-04-02T12:54:38+09:00https://sanbio.evoworx.net/en/news/sanbio-presents-at-the-annual-european-stroke-organization-conference-%ef%bc%88170kb%ef%bc%89/2020-04-02T12:55:01+09:00https://sanbio.evoworx.net/en/news/sanbio-announces-pricing-of-initial-public-offering-on-tokyo-stock-exchange-%ef%bc%88253kb%ef%bc%89/2020-04-02T12:52:14+09:00https://sanbio.evoworx.net/en/news/sanbio-announces-joint-development-and-license-agreement-with-sumitomo-dainippon-pharma-%ef%bc%88243kb%ef%bc%89/2020-04-02T12:51:57+09:00https://sanbio.evoworx.net/en/news/sanbio-announces-appointment-of-chief-medical-officer-%ef%bc%88134kb%ef%bc%89/2020-04-02T12:50:41+09:00https://sanbio.evoworx.net/en/news/sanbio-announces-the-first-public-presentation-of-data-from-its-on-going-human-clinical-trial-of-cell-therapy-for-chronic-stroke-disability-%ef%bc%88259kb%ef%bc%89/2020-04-02T12:53:48+09:00https://sanbio.evoworx.net/en/news/sanbio-announces-the-completion-of-enrollment-of-its-clinical-trial-of-cell-therapy-for-chronic-stroke-deficits-%ef%bc%8855kb%ef%bc%89/2020-04-02T12:53:30+09:00https://sanbio.evoworx.net/en/news/sanbio-announces-fda-clearance-for-the-initiation-of-a-phase-i-2a-clinical-trial-testing-their-cell-therapy-product-sb623-in-patients-with-traumatic-brain-injury-%ef%bc%88118kb%ef%bc%89/2020-04-02T12:51:18+09:00https://sanbio.evoworx.net/en/news/stanford-based-research-seeks-to-help-stroke-patients/2020-04-02T12:59:04+09:00https://sanbio.evoworx.net/en/news/northwestern-medicine-researchers-investigate-stem-cell-therapy-for-stroke/2020-04-01T21:03:51+09:00https://sanbio.evoworx.net/en/news/sanbio-announces-successful-enrollment-of-the-second-cohort-of-patients-in-its-clinical-trial-of-stem-cell-therapy-for-chronic-stroke-%ef%bc%88255kb%ef%bc%89/2020-04-02T12:53:11+09:00https://sanbio.evoworx.net/en/news/researchers-testing-stem-cells-as-treatment-for-stroke-recovery-%ef%bc%88117kb%ef%bc%89/2020-04-02T12:50:18+09:00https://sanbio.evoworx.net/en/news/researchers-at-upmc-stanford-test-stem-cells-to-enhance-stroke-recovery-%ef%bc%8885kb%ef%bc%89/2020-04-01T21:04:28+09:00https://sanbio.evoworx.net/en/news/sanbio-announces-enrollment-of-first-cohort-of-patients-in-its-clinical-trial-of-stem-cell-therapy-for-chronic-stroke-%ef%bc%88239kb%ef%bc%89/2020-04-02T12:50:57+09:00https://sanbio.evoworx.net/en/news/award-bioscience-sanbio-creates-better-odds-for-stroke-recovery-%ef%bc%88133kb%ef%bc%89/2020-04-01T21:01:39+09:00https://sanbio.evoworx.net/en/news/stem-cell-applications-hasten-into-the-clinic/2020-04-02T12:59:12+09:00https://sanbio.evoworx.net/en/news/sanbio-announces-first-patient-treated-at-stanford-with-novel-cell-therapy-sb623-in-clinical-trial-of-stable-stroke-patients-%ef%bc%889kb%ef%bc%89/2020-04-02T12:51:39+09:00https://sanbio.evoworx.net/en/news/sanbio-announces-site-opening-of-phase-1-2a-clinical-trial-of-novel-cell-therapy-in-stable-stroke-patients-at-university-of-pittsburgh-medical-center-%ef%bc%889kb%ef%bc%89/2020-04-02T12:52:52+09:00https://sanbio.evoworx.net/en/news/tesla-motors-sanbio-win-first-salesforce-com-japan-us-emerging-leaders-awards/2020-04-02T12:59:46+09:00https://sanbio.evoworx.net/en/news/stanford-and-sanbio-announce-a-clinical-trial-of-cell-therapy-for-stroke-disability-%ef%bc%8852kb%ef%bc%89/2020-04-02T12:58:55+09:00https://sanbio.evoworx.net/en/news/dainippon-sumitomo-pharma-and-sanbio-collaborate-on-cell-therapy-for-stroke-recovery/2020-04-01T21:01:46+09:00https://sanbio.evoworx.net/en/news/sanbio-receives-fda-clearance-to-initiate-cell-therapy-clinical-studies-for-stroke-recovery-%ef%bc%889kb%ef%bc%89/2020-04-02T12:57:09+09:00https://sanbio.evoworx.net/en/news/teijin-signs-agreement-for-sanbios-new-drug-for-stroke-therapy-major-entry-into-regenerative-medicine-market/2020-04-02T12:59:39+09:00https://sanbio.evoworx.net/en/news/hiroyasu-narita-joins-sanbio-as-the-head-of-clinical-development/2020-10-09T11:13:11+09:00https://sanbio.evoworx.net/en/news/akihiro-tsujimura-appointed-executive-vice-president-and-coo/2020-10-09T11:13:22+09:00https://sanbio.evoworx.net/en/news/additional-analytical-results-of-the-us-based-phase-2b-clinical-trial-of-regenerative-cell-medicine-sb623-for-the-treatment-of-chronic-motor-deficit-from-ischemic-stroke-and-review-of-plans-to-initia/2020-10-09T11:13:16+09:00https://sanbio.evoworx.net/en/news/christopher-horan-joins-sanbio-as-corporate-officer-and-chief-technical-operations-officer/2020-10-09T11:13:27+09:00https://sanbio.evoworx.net/en/news/financial-results-briefing-for-fiscal-year-ended-january-31-2020-qa-summary/2020-10-09T11:13:33+09:00https://sanbio.evoworx.net/en/news/joint-research-to-investigate-the-efficacy-of-sb623-in-the-treatment-of-traumatic-brain-injury-at-subacute-phase/2020-10-09T11:13:39+09:00https://sanbio.evoworx.net/en/news/joint-research-with-view-to-developing-regenerative-medicine-product-for-type-1-diabetes-by-producing-pancreatic-beta-cells-through-direct-reprogramming-of-bone-marrow-derived-mesenchymal-stem-cells/2020-10-09T11:13:44+09:00https://sanbio.evoworx.net/en/news/sanbio-and-sumitomo-dainippon-pharma-announce-topline-results-from-a-phase-2b-study-in-the-u-s-evaluating-sb623-a-regenerative-cell-medicine-for-the-treatment-of-patients-with-chronic-stroke/2020-10-09T11:28:31+09:00https://sanbio.evoworx.net/en/news/sanbio-to-announce-the-results-of-a-phase-2-stemtra-trial-regarding-the-use-of-regenerative-cell-medicine-sb623-as-a-treatment-for-tbi-at-an-annual-scientific-meeting-of-the-american-association-of-ne/2020-10-09T11:28:19+09:00https://sanbio.evoworx.net/en/news/sanbio-to-give-an-encore-presentation-on-the-results-of-a-phase-2-stemtra-trial-regarding-the-use-of-regenerative-cell-medicine-sb623-as-a-treatment-for-tbi-at-the-14th-korea-japan-joint-confe/2020-10-09T11:27:49+09:00https://sanbio.evoworx.net/en/news/sanbio-announces-sb623-regenerative-cell-therapy-for-traumatic-brain-injury-has-received-ministry-of-health-labour-and-welfare-mhlw-sakigake-designation/2020-10-09T11:27:40+09:00https://sanbio.evoworx.net/en/news/aans-2019-sb623-demonstrated-statistically-significant-improvement-in-motor-function-among-patients-with-chronic-motor-deficit-from-traumatic-brain-injury-tbi/2020-10-09T11:27:44+09:00https://sanbio.evoworx.net/en/news/sb623-an-investigational-product-granted-advanced-therapy-medicinal-product-classification-by-european-medicines-agency/2020-10-09T11:27:35+09:00https://sanbio.evoworx.net/en/news/bijan-nejadnik-m-d-appointed-as-chief-medical-officer-of-sanbio/2020-10-09T11:27:30+09:00https://sanbio.evoworx.net/en/news/sanbio-announced-the-results-of-the-phase-2-stemtra-trial-of-sb623-as-a-treatment-for-chronic-motor-deficit-from-traumatic-brain-injury-was-presented-at-the-military-health-system-research-symposium-2/2020-10-09T11:27:25+09:00https://sanbio.evoworx.net/en/news/sanbio-announced-the-results-of-the-phase-2-stemtra-trial-of-sb623-as-a-treatment-for-chronic-motor-deficit-from-traumatic-brain-injury-at-2019-world-federation-of-neurosurgical-societies-special-wor/2020-10-09T11:27:21+09:00https://sanbio.evoworx.net/en/news/sanbio-granted-regenerative-medicine-advanced-therapy-designation-from-the-u-s-fda-for-sb623-for-the-treatment-of-chronic-neurological-motor-deficits-secondary-to-traumatic-brain-injury/2020-10-09T11:27:16+09:00https://sanbio.evoworx.net/en/news/agreement-on-joint-research-into-sb623-for-indication-of-retinal-disease/2020-10-09T11:27:11+09:00https://sanbio.evoworx.net/en/news/sanbio-and-sumitomo-dainippon-pharma-announce-a-termination-of-a-joint-development-and-license-agreement-for-regenerative-cell-medicine-sb623-for-chronic-stroke-in-north-america/2020-10-09T11:27:06+09:00https://sanbio.evoworx.net/en/news/qa-regarding-announcements-on-december-13-2019-concerning-consolidated-financial-results-for-the-nine-months-ended-october-31-2019-and-decision-to-terminate-a-joint-devel/2020-10-09T11:27:01+09:00https://sanbio.evoworx.net/en/news/message-from-representative-director-and-president-keita-mori-regarding-disclosures-made-on-december-13-2019/2020-10-09T11:26:56+09:00https://sanbio.evoworx.net/en/news/the-status-of-domestic-approval-filing-for-regenerative-cell-medicine-sb623-for-treatment-of-chronic-effects-associated-with-traumatic-brain-injury/2020-12-15T15:04:17+09:00https://sanbio.evoworx.net/en/news/publication-of-stemtra-phase-2-interim-analysis-for-sb623-in-neurology/2021-01-05T08:20:23+09:00https://sanbio.evoworx.net/en/news/sanbio-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference/2021-01-20T13:34:48+09:00https://sanbio.evoworx.net/en/news/head-of-regulatory-affairs-japan-kazumi-sawaguchi-ph-d-gave-a-presentation-at-5th-dia-cell-and-gene-therapy-products-symposium-in-japan/2021-02-22T14:12:35+09:00https://sanbio.evoworx.net/en/news/presentation-of-stemtra-phase-2-trial-results-at-the-44th-annual-meeting-of-the-japan-society-of-neurotraumatology/2021-03-03T19:13:55+09:00https://sanbio.evoworx.net/en/news/publication-comparing-outcome-measures-for-persons-with-chronic-traumatic-brain-injury-in-expert-review-of-neurotherapeutics/2021-11-10T18:13:42+09:00https://sanbio.evoworx.net/en/news/business-partnership-for-development-and-commercialization-of-medical-device-implant-utilizing-msc2-for-the-regeneration-of-esophageal-tissue-in-humans/2021-11-16T18:10:38+09:00https://sanbio.evoworx.net/en/news/sanbio-joins-the-newly-formed-national-tbi-registry-coalition-ntrc-as-a-founding-member-organization/2021-12-15T17:40:02+09:00https://sanbio.evoworx.net/en/news/notice-regarding-completion-of-approval-filing-for-japan-sb623-chronic-tbi-program/2022-03-07T18:17:39+09:00https://sanbio.evoworx.net/en/news/sb623-demonstrated-sustained-improvement-in-motor-impairment-up-to-48-weeks-and-associated-with-improvement/2022-04-05T15:19:31+09:00https://sanbio.evoworx.net/en/news/on-april-7-nurologylive-published-an-interview-with-dr-peter-mcallister-regarding-the-final-analysis-of-the-phase-2-stemtra-trial/2022-04-25T11:13:26+09:00https://sanbio.evoworx.net/en/news/notice-of-patent-acquisition-for-r-sat-a-distribution-management-and-administration-schedule-support-system-for-regenerative-medicine-products-jointly-developed-with-suzuken-co-ltd/2022-05-09T15:13:38+09:00https://sanbio.evoworx.net/en/news/andrew-liu-to-join-sanbio-as-chief-strategy-officer/2022-06-01T16:15:36+09:00https://sanbio.evoworx.net/en/news/keizo-nakada-to-join-sanbio-as-corporate-officer-and-head-of-production/2022-07-01T15:02:58+09:00https://sanbio.evoworx.net/en/news/update-on-status-of-manufacturing-and-marketing-approval-for-sb623-chronic-traumatic-brain-injury-tbi-program-in-japan/2022-07-22T15:07:33+09:00https://sanbio.evoworx.net/en/news/notice-regarding-appointment-of-new-corporate-officers/2022-08-01T15:04:46+09:00https://sanbio.evoworx.net/en/news/further-update-on-status-of-manufacturing-and-marketing-approval-for-sb623-chronic-traumatic-brain-injury-tbi-program-in-japan/2022-10-20T15:03:05+09:00https://sanbio.evoworx.net/en/news/joint-research-agreement-for-sb623-targeting-alzheimers-type-dementia/2022-11-29T15:03:34+09:00https://sanbio.evoworx.net/en/news/presentation-of-phase-2-stemtra-trial-results-at-the-14th-world-congress-on-brain-injury/2022-12-22T15:12:08+09:00https://sanbio.evoworx.net/en/news/establishment-of-in-house-facility-and-acquisition-of-license-for-packaging-labeling-and-storage-of-regenerative-medicine-products/2022-12-21T15:04:10+09:00https://sanbio.evoworx.net/en/news/further-update-on-status-of-manufacturing-and-marketing-approval-for-sb623-chronic-traumatic-brain-injury-tbi-program-in-japan-2/2023-06-14T15:09:31+09:00https://sanbio.evoworx.net/en/news/further-update-on-status-of-manufacturing-and-marketing-approval-for-sb623-chronic-traumatic-brain-injury-tbi-program-in-japan-3/2023-09-05T11:24:59+09:00https://sanbio.evoworx.net/en/news/further-update-on-status-of-manufacturing-and-marketing-approval-for-sb623-chronic-traumatic-brain-injury-tbi-program-in-japan-4/2023-12-20T15:13:42+09:00https://sanbio.evoworx.net/en/news/further-update-on-status-of-manufacturing-and-marketing-approval-for-sb623-chronic-traumatic-brain-injury-tbi-program-in-japan-5/2024-03-19T08:57:56+09:00https://sanbio.evoworx.net/en/news/further-update-on-status-of-manufacturing-and-marketing-approval-for-sb623-chronic-traumatic-brain-injury-tbi-program-in-japan-6/2024-03-26T16:24:27+09:00https://sanbio.evoworx.net/en/news/further-update-on-status-of-manufacturing-and-marketing-approval-for-sb623-chronic-traumatic-brain-injury-tbi-program-in-japan-7/2024-06-20T15:15:31+09:00https://sanbio.evoworx.net/en/news/further-update-on-status-of-manufacturing-and-marketing-approval-for-sb623-chronic-traumatic-brain-injury-tbi-program-in-japan-8/2024-07-18T17:20:33+09:00https://sanbio.evoworx.net/en/news/results-of-basic-research-publication-of-an-article-on-the-neuronal-activity-and-network-formation-promotion-of-the-key-development-product-sb623/2024-07-18T17:22:07+09:00https://sanbio.evoworx.net/en/news/notice-concerning-notice-of-allowance-of-new-patent-for-cell-therapy-using-sb623-for-chronic-ischemic-stroke-in-the-us/2024-07-29T18:04:29+09:00https://sanbio.evoworx.net/en/news/sanbio-obtains-marketing-approval-for-akuugo%f0%9f%84%ac-suspension-for-intracranial-implantation-inn-vandefitemcel-as-a-therapeutic-agent-for-improving-chronic-motor-paralysis-fr/2024-07-31T14:44:15+09:00https://sanbio.evoworx.net/en/news/positive-results-of-key-development-product-sb623-for-chronic-effects-of-traumatic-brain-injury-including-sustained-motor-function-improvement-up-to-48-weeks-published-in-neurology/2024-09-05T17:17:23+09:00https://sanbio.evoworx.net/en/news/mori-president-ceo-will-be-a-panelist-at-navigating-biopharma-innovation-across-the-pacific-hosted-by-the-u-s-embassy-and-the-japan-society-of-northern-california-on-november-11/2024-11-11T16:00:57+09:00https://sanbio.evoworx.net/en/news/1stproductionrun/2024-11-15T13:11:07+09:00https://sanbio.evoworx.net/en/news/the-yield-results-of-the-second-commercial-production-run-for-akuugo%f0%9f%84%ac-suspension-for-intracranial-implantation/2024-12-06T10:52:53+09:00https://sanbio.evoworx.net/en/news/publication-of-an-article-in-molecular-therapy-demonstrates-that-sb623-improvescortical-excitability-in-rats-with-focal-cerebral-ischemia/2025-01-07T15:36:36+09:00https://sanbio.evoworx.net/en/news/keio_saiseiiryou/2025-01-14T16:00:57+09:00https://sanbio.evoworx.net/en/news/the-results-of-the-second-commercial-production-run-to-meet-the-approval-conditions-for-the-shipment-of-akuugo%f0%9f%84%ac-suspension-for-intracranial-implantation/2025-02-10T11:29:45+09:00https://sanbio.evoworx.net/en/news/neurotraumareports/2025-02-12T10:29:27+09:00https://sanbio.evoworx.net/en/news/20250418-2/2025-04-18T10:10:20+09:00https://sanbio.evoworx.net/en/news/manufacturingresult/2025-05-29T13:40:50+09:00https://sanbio.evoworx.net/en/news/keita-mori-representative-director-and-president-of-sanbio-appointed-chairman-of-samurai-biotech-association/2025-05-30T13:15:00+09:00https://sanbio.evoworx.net/en/news/notice-of-completion-of-application-for-partial-change-approval-of-akuugo%f0%9f%84%ac-suspension-for-intracranial-implantation/2025-06-12T10:56:11+09:00https://sanbio.evoworx.net/en/news/notice-regarding-revision-of-expected-approval-timing-for-partial-changes-to-akuugorsuspension-for-intracranial-implantation/2025-06-25T13:28:51+09:00https://sanbio.evoworx.net/en/news/keita-mori-ceo-will-be-a-panelist-at-us-japan-healthcare-connection-hosted-by-the-japan-society-of-northern-california-2025-9-19/2025-09-09T16:13:51+09:00https://sanbio.evoworx.net/en/news/keita-mori-president-ceo-participated-as-a-speaker-in-the-sponsored-seminar-at-biojapan-2025-october-9-2025/2025-10-09T14:32:41+09:00https://sanbio.evoworx.net/en/news/two-corporate-officers/2025-12-08T14:08:09+09:00https://sanbio.evoworx.net/en/news/sanbio-obtains-partial-change-approval-forakuugo%f0%9f%84%ac-suspension-for-intracranial-implantation/2025-12-09T14:45:56+09:00https://sanbio.evoworx.net/en/news/1585-2/2026-04-02T23:19:09+09:00https://sanbio.evoworx.net/en/news/keita-mori-ceo-spoke-at-miyamans-venture-talk-vol-15-exploring-brain-regeneration-with-mitsuru-miyata-and-keita-mori-hosted-by-link-j-april-9-2026/2026-04-09T11:51:49+09:00